A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Inclusion Criteria (All Parts): 1. Males and females ≥ 18 years of age. 2. Life expectancy of ≥ 3 months. 3. Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2. 4. Histopathologically confirmed diagnosis of CLL (medical record is acceptable), as per the World Health Organization 2016 classification. 5. At least 1 criterion for measurable disease per International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 6. For Cohort 1 only: 1. Participant must be in a partial response (PR) or partial response with lymphocytosis (PR-L) and measurable residual disease positive (MR…